medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2013, Number 607

<< Back Next >>

Rev Med Cos Cen 2013; 70 (607)

Fármacos hipolipemiantes

Vindas MCA

Language: Spanish
References: 27
Page: 529-537
PDF size: 227.22 Kb.


ABSTRACT

Atherosclerosis is the primary pathophysiologic process in the development of cardiovascular disease, this remains the leading cause of death worldwide, and dyslipidemia is one of the main elements involved in the pathogenesis of atherosclerosis. Although studies have shown that cardiovascular disease is multifactorial (genetic, geographical variations), dyslipidemia associated with other risk factors exponentially increases the chances of having this condition. Patients with atherosclerotic disease or those suffering cardiovascular events often have alterations in blood levels of lipoproteins (VLDL, LDL, HLD, triglycerides). For this reason it is vital to address the disease properly, taking appropriate measures for each patient including lifestyle changes (adequate nutrition, cardiovascular exercise, smoking cessation, control of hypertension and diabetes), and lipid-lowering drugs when these are indicated.


REFERENCES

  1. Arguedas J. Estatinas. Actualización Médica Periódica, 2012, Número 4.

  2. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hiperlipidemia. Am J Cardiol, 1997; 80(5): 608.

  3. Bertram G. Katzung. Fármacos para el tratamiento de Dislipidemias. Farmacología Básica y Clínica. 2009, 11ª edición: 605-21.

  4. Binder EF, Williams DB, Schechtman KB, et al. Effects of hormone replacement therapy on serum lipids in elderly women, a randomized, placebocontrolled trial. Ann Intern Med, 2001; 134: 754.

  5. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24): 2255.

  6. Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R, Joyal S, Hill K, Pfeffer M, Skene A. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med, 2004; 350: 1495-504.

  7. Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardio, 2006; 97(8A): 77C.

  8. Davidson M, Dillon M, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke S. Colesevelam Hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med, 1999; 159(16): 1893.

  9. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol, 2002; 90(10): 1092.

  10. Goldfine A. Statins: Is It Really Time to Reassess Benefits and Risks? N Engl J Med, 2012; 366: 1752-55.

  11. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT- 335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol, 2009; 103: 515.

  12. Jackevicius C, Chou M, Ross J, Shah N, Krumholz H. Generic Atorvastatin and Health Care Costs. N Engl J Med, 2012, 366;3.

  13. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, 2010; 375(9729): 1875.

  14. Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J. Prevención y tratamiento de la aterosclerosis. Harrison Principios de Medicina Interna. 2005, 16ª edición: 1581-82.

  15. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Me, 2008; 358(14): 1431.

  16. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366(9500): 1849.

  17. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med, 2001; 110(5): 352.

  18. La Rosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J, Gotto A, Greten H, Kastelein J, Shepherd J, Wenger D. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med, 2005; 352: 1425-35.

  19. Lanford RE, Estlack L, White AL. Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface. J Lipid Res, 1996; 37: 2055.

  20. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol, 2009; 104(1): 74.

  21. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, Koenig W, Libby P, Lorenzatti A, MacFadyen J, Nordestgaard B, Shepherd J, Willerson J, Glynn R. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008; 359: 2195-207.

  22. Serrano C. Indicaciones de los Hipolipemiantes. IT del Sistema Nacional de Salud, Portugalete, Bizkaia, 2010, Volumen 34, Nº 2.

  23. Taylor A, Villines T, Stanek E, Devine P, Griffen L, Miller M, Weissman N, and Turco M. Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thicknes. N Eng J Med, 2009; 361: 2113-22.

  24. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Eng J Med, 2010; 362: 1575-85.

  25. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatininduced arrest in progression of renal disease. Cardiology, 2004; 102(1): 52.

  26. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 875.

  27. Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med, 2012; 156: 560.




2020     |     www.medigraphic.com